Abstract | CONTEXT: OBJECTIVE: DESIGN: In a prospective, crossover trial, 48 women with PCOS were randomized to either simvastatin plus OCP for 12 wk followed by OCP alone for an additional 12 wk, or to OCP alone for 12 wk and, subsequently, simvastatin plus OCP for an additional 12 wk. Evaluations were performed at baseline, after 12 wk (crossover), and after 24 wk. Data were analyzed using a random effects model. SETTING: The study was conducted in an academic medical center. PRIMARY OUTCOME: RESULTS: CONCLUSIONS:
|
Authors | Beata Banaszewska, Leszek Pawelczyk, Robert Z Spaczynski, James Dziura, Antoni J Duleba |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 92
Issue 2
Pg. 456-61
(Feb 2007)
ISSN: 0021-972X [Print] United States |
PMID | 17105841
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Contraceptives, Oral, Combined
- Estrogens
- Hypolipidemic Agents
- Pituitary Hormones
- Testosterone
- Ethinyl Estradiol
- Desogestrel
- Simvastatin
|
Topics |
- Adult
- Contraceptives, Oral, Combined
(administration & dosage)
- Cross-Over Studies
- Desogestrel
(administration & dosage)
- Drug Therapy, Combination
- Estrogens
(administration & dosage)
- Ethinyl Estradiol
(administration & dosage)
- Female
- Humans
- Hypolipidemic Agents
(administration & dosage)
- Pituitary Hormones
(blood)
- Polycystic Ovary Syndrome
(blood, drug therapy)
- Prospective Studies
- Simvastatin
(administration & dosage)
- Testosterone
(blood)
- Treatment Outcome
|